On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
about
An Interoperability Platform Enabling Reuse of Electronic Health Records for Signal Verification StudiesItalian monitoring registries: a tool for a safer use of innovative drugs? Data from the national pharmacovigilance system.Drugs and dilated cardiomyopathies: A case/noncase study in the French PharmacoVigilance Database.Comparison and validation of data-mining indices for signal detection: using the Korean national health insurance claims database.Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase.Data mining for signal detection of adverse event safety data.Effect of reporting bias in the analysis of spontaneous reporting data.A novel signal detection algorithm for identifying hidden drug-drug interactions in adverse event reportsDevelopment and Application of an Alert System to Detect Cases of Food Poisoning in Japan.Systematic Adverse Drug Reaction Monitoring of Patients Under Newer Antiepileptic Drugs Using Routine Clinical Data of Inpatients.Atypical antipsychotic medications and hyponatremia in older adults: a population-based cohort study.Signal detection methodologies to support effective safety management.The application of knowledge discovery in databases to post-marketing drug safety: example of the WHO database.Drug-drug interactions with imatinib: An observational study.Do GLP-1-based therapies increase cancer risk?Estimating time-to-onset of adverse drug reactions from spontaneous reporting databases.Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.Drug-induced parkinsonism: a review of 17 years' experience in a regional pharmacovigilance center in France.Safety aspects of antiepileptic drugs--focus on pharmacovigilance.Drug-drug interaction discovery and demystification using Semantic Web technologies.The effect of exposure misclassification in spontaneous ADR reports on the time to detection of product-specific risks for biologicals: a simulation study.Cardiotoxicity in targeted therapy for breast cancer: A study of the FDA adverse event reporting system (FAERS).Quinolone antibiotics and suicidal behavior: analysis of the World Health Organization's adverse drug reactions database and discussion of potential mechanisms.Thromboembolic adverse event study of combined estrogen-progestin preparations using Japanese Adverse Drug Event Report database.INDI: a computational framework for inferring drug interactions and their associated recommendations.Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports.Reports of sexual disorders related to serotonin reuptake inhibitors in the French pharmacovigilance database: an example of underreporting.Gingival bleeding, a possible "serious" adverse drug reaction: An observational study in the French PharmacoVigilance Database.Prescribed drugs and violence: a case/noncase study in the French PharmacoVigilance Database.Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.Contraceptives as possible risk factors for postpartum depression: A retrospective study of the food and drug administration adverse event reporting system, 2004-2015.Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
P2860
Q28604303-EC22CFE5-1889-4275-BDC6-8EE561E2C294Q31144143-9C800EA7-A3AB-4FA3-89EC-3D1EAE3CF317Q33692818-CC54A57A-B8C9-4DC6-97EB-303F09EE8C52Q34082600-93C25507-6223-48CE-9DBC-ED5E04D32266Q34381361-3B0AFA8A-0B3F-49C2-95CB-C3B5CB627EFFQ34553937-6AAE2A12-8FAA-4A45-A126-43E8F0329B2AQ35400772-D18933F9-0D64-41A5-AA42-C8D1D6EDCEC3Q35619067-2A924CDB-1FFC-40E6-ACFC-6C4E4A835742Q36032190-2F84F163-5701-4542-943E-3F50D2134151Q36072406-EBCCF9E3-B95F-4CBE-8923-6F76A33E2D61Q36785625-7240D85B-D88D-4099-846A-01679E8CA761Q36905865-A2AA5ACC-DB9D-43C4-B299-95466ED1A7A7Q37076419-8AE28E21-4B54-4B7E-A00A-A8DCB965D693Q37328934-A82DBBDB-5EE6-476D-A77C-6AA0747735D2Q37577143-86D1B0E2-E435-498F-92F2-4A776E387C34Q37581719-66A1FBED-2AA3-4CB0-9CEA-EC5DD1206B68Q37877271-DC62B123-D799-4A57-B7D1-57B7C9EEB2C4Q37889802-1D27D760-00D8-4345-B068-D904BADD0A65Q37954227-C4290967-BC49-4ADB-823C-355F2E2D289AQ38383012-537933E6-485E-4E56-92CE-1CACE3DC759BQ38931121-C3277747-BA2C-490C-989A-B8862712E474Q40218182-881A603E-10A9-4156-8EE9-5B842ED3016CQ40782394-61BDC795-3BBB-4678-BA60-DEF6580D49C8Q41090535-F0344D50-39DE-4B9E-A62D-D60FD862A77BQ42280497-0CF4AF89-3E4E-462F-A29B-8F5EF2FCBC17Q43958079-850421F2-2075-4CB4-B017-0FF5A8D81743Q44731914-8C495D41-81CE-46F0-91E3-B8D02DC859AAQ45916557-7888A6C5-736B-47CE-A211-33FDE2AF6ABCQ48190936-F7E232E7-72C8-4EDF-AB19-00ACCA5D56FBQ50556141-849B4DED-9670-4BD1-ADFE-70C572E79D16Q51846797-7B93622C-D193-448C-86B0-B2884A2EC203Q53833893-1127E621-E958-49D1-ABB6-A80AEC5F856AQ54420490-ABA97443-C66A-4FB4-9AF5-0A7307A2C28A
P2860
On the assessment of adverse drug reactions from spontaneous reporting systems: the influence of under-reporting on odds ratios.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
On the assessment of adverse d ...... nder-reporting on odds ratios.
@en
On the assessment of adverse d ...... nder-reporting on odds ratios.
@nl
type
label
On the assessment of adverse d ...... nder-reporting on odds ratios.
@en
On the assessment of adverse d ...... nder-reporting on odds ratios.
@nl
prefLabel
On the assessment of adverse d ...... nder-reporting on odds ratios.
@en
On the assessment of adverse d ...... nder-reporting on odds ratios.
@nl
P2093
P356
P1476
On the assessment of adverse d ...... nder-reporting on odds ratios.
@en
P2093
Eugène P van Puijenbroek
Jacques W van der Hofstede
Peter G M van der Heijden
P304
P356
10.1002/SIM.1157
P407
P577
2002-07-01T00:00:00Z